Author

Michele L. Coia

Observed names: Michele Coia, Michele L Coia

Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Program for Appropriate Technology in Health

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Program for Appropriate Technology in Health, Johns Hopkins University, University of Antwerp, Eastern Virginia Medical School, Rhode Island Hospital, University of Tampere

OpenAlex ID: A5082737003

Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus Vaccine

2006 · Timo Vesikari, David O. Matson, et al. · New England Journal of Medicine · 1,875

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial

2010 · K Zaman, Dang Duc Anh, et al. · The Lancet · 826

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial

2010 · George E Armah, Samba O Sow, et al. · The Lancet · 657

Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries)

2007 · Timo Vesikari, Robbin Itzler, et al. · International Journal of Infectious Diseases · 93

Rotateq® Reduced Hospitalizations and Emergency Department Visits for Rotavirus Acute Gastroenteritis: Assessing the Robustness of the Results

2008 · Timo Vesikari, Robbin Itzler, et al. · Archives of Disease in Childhood · 1

Seguridad y eficacia de una vacuna antirrotavírica reagrupada humano-bovina (WC3) pentavalente

2006 · Timo Vesikari, David O. Matson, et al.

Безопасность и эффективность пятивалентной человеческой- бычьей (WC3) реассортативной антиротавирусной вакцины

2006 · Timo Vesikari, David O. Matson, et al.

Works count: 7

Citation count: 3,452

H-index: 4

I10-index: 4